Improvement in insulin sensitivity following intensive insulin therapy and association of glucagon with long-term diabetes remission

J Int Med Res. 2016 Dec;44(6):1543-1550. doi: 10.1177/0300060516668433. Epub 2016 Nov 11.

Abstract

Objective To investigate the role of the acute glucagon response in the long-term remission of newly diagnosed type 2 diabetes mellitus following short-term intensive insulin therapy (IIT). Methods Ten patients with newly diagnosed type 2 diabetes mellitus received IIT. Intravenous glucose tolerance tests and the clamp technique were performed pre- and post-IIT. Remission was defined as maintenance of target glycaemic control without anti-diabetic agents for 1 year. Results The remission rate was 50% (5/10). There were no differences in the acute insulin response or glucose infusion rate between groups. The acute glucagon response (AGR) in the remission group pre-IIT was significantly higher than that in the non-remission group (mean 163.02 pg/mL/min vs. mean 16.29 pg/mL/min). The mean AGR post-IIT was lower in the remission group than that in the non-remission group (0 pg/mL/min vs. 19.91 pg/mL/min). Spearman analysis indicated that the AGR pre-IIT and the change in the AGR were correlated with remission (r = 0.731). Conclusion The insulin-mediated glucose disposal rate was significantly improved with the normalization of blood glucose levels following transient IIT. Subjects with a higher AGR pre-IIT and a greater AGR decrease post-IIT displayed a greater likelihood of long-term remission.

Keywords: glucagon; insulin sensitivity; intensive insulin therapy; long-term remission; type 2 diabetes mellitus.

MeSH terms

  • Adult
  • Aged
  • Blood Glucose / metabolism*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Fasting
  • Female
  • Glucagon / administration & dosage
  • Glucagon / blood*
  • Glucose Tolerance Test
  • Humans
  • Hypoglycemic Agents / blood
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / blood
  • Insulin / therapeutic use*
  • Insulin Resistance*
  • Male
  • Middle Aged
  • Remission Induction

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Glucagon